BG63144B1 - Офталмологичен състав, съдържащ йонночувствителенхидрофилен полимер и неорганична сол в съотношение, водещо до понижен вискозитет - Google Patents

Офталмологичен състав, съдържащ йонночувствителенхидрофилен полимер и неорганична сол в съотношение, водещо до понижен вискозитет Download PDF

Info

Publication number: BG63144B1
Authority: BG; Bulgaria
Prior art keywords: weight; viscosity; composition according; polymer; timolol
Prior art date: 1994-03-31

Application number

BG100914A

Other languages

Bulgarian (bg)

English (en)

Other versions

BG100914A (en

Inventor

Kari Lehmussaari

Eija Vartiainen

Timo Reunamaeki

Olli Oksala

Sakari Alaranta

Esko Pohjala

Original Assignee

Leiras Oy

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-03-31

Filing date

1996-10-16

Publication date

2001-05-31

1996-10-16 Application filed by Leiras Oy filed Critical Leiras Oy

1997-07-31 Publication of BG100914A publication Critical patent/BG100914A/xx

2001-05-31 Publication of BG63144B1 publication Critical patent/BG63144B1/bg

Links

239000000203 mixture Substances 0.000 title claims abstract description 66
229920001477 hydrophilic polymer Polymers 0.000 title claims abstract description 6
229910017053 inorganic salt Inorganic materials 0.000 title description 4
229920000642 polymer Polymers 0.000 claims abstract description 31
150000003839 salts Chemical class 0.000 claims abstract description 21
239000003755 preservative agent Substances 0.000 claims abstract description 9
230000002335 preservative effect Effects 0.000 claims abstract description 8
239000000080 wetting agent Substances 0.000 claims abstract description 6
239000000872 buffer Substances 0.000 claims abstract description 5
229920002125 Sokalan® Polymers 0.000 claims description 27
PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 24
235000002639 sodium chloride Nutrition 0.000 claims description 22
TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims description 18
229960004605 timolol Drugs 0.000 claims description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
238000009472 formulation Methods 0.000 claims description 11
229960000454 timolol hemihydrate Drugs 0.000 claims description 11
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 9
150000001875 compounds Chemical class 0.000 claims description 7
-1 karteolol Chemical compound 0.000 claims description 7
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 6
239000011780 sodium chloride Substances 0.000 claims description 5
239000002876 beta blocker Substances 0.000 claims description 4
229940097320 beta blocking agent Drugs 0.000 claims description 4
230000000694 effects Effects 0.000 claims description 4
150000002500 ions Chemical class 0.000 claims description 4
239000001488 sodium phosphate Substances 0.000 claims description 4
229910000162 sodium phosphate Inorganic materials 0.000 claims description 4
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 4
239000003242 anti bacterial agent Substances 0.000 claims description 3
239000001103 potassium chloride Substances 0.000 claims description 3
235000011164 potassium chloride Nutrition 0.000 claims description 3
235000011008 sodium phosphates Nutrition 0.000 claims description 3
QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 claims description 2
QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 claims description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 2
239000000219 Sympatholytic Substances 0.000 claims description 2
239000002260 anti-inflammatory agent Substances 0.000 claims description 2
230000003110 anti-inflammatory effect Effects 0.000 claims description 2
239000000030 antiglaucoma agent Substances 0.000 claims description 2
229960004324 betaxolol Drugs 0.000 claims description 2
230000003115 biocidal effect Effects 0.000 claims description 2
229910021538 borax Inorganic materials 0.000 claims description 2
239000003795 chemical substances by application Substances 0.000 claims description 2
239000003112 inhibitor Substances 0.000 claims description 2
IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 claims description 2
229960000831 levobunolol Drugs 0.000 claims description 2
229960002704 metipranolol Drugs 0.000 claims description 2
229960001416 pilocarpine Drugs 0.000 claims description 2
PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 claims description 2
229960002508 pindolol Drugs 0.000 claims description 2
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims description 2
239000001632 sodium acetate Substances 0.000 claims description 2
235000017281 sodium acetate Nutrition 0.000 claims description 2
239000001509 sodium citrate Substances 0.000 claims description 2
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 2
235000011083 sodium citrates Nutrition 0.000 claims description 2
235000010339 sodium tetraborate Nutrition 0.000 claims description 2
239000000126 substance Substances 0.000 claims description 2
230000000948 sympatholitic effect Effects 0.000 claims description 2
229940127230 sympathomimetic drug Drugs 0.000 claims description 2
BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 claims description 2
229940121363 anti-inflammatory agent Drugs 0.000 claims 1
CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 claims 1
BLWNYSZZZWQCKO-UHFFFAOYSA-N metipranolol hydrochloride Chemical compound [Cl-].CC(C)[NH2+]CC(O)COC1=CC(C)=C(OC(C)=O)C(C)=C1C BLWNYSZZZWQCKO-UHFFFAOYSA-N 0.000 claims 1
150000004965 peroxy acids Chemical class 0.000 claims 1
239000000243 solution Substances 0.000 abstract description 37
239000003814 drug Substances 0.000 abstract description 7
238000010521 absorption reaction Methods 0.000 abstract description 6
229940079593 drug Drugs 0.000 abstract description 6
239000007864 aqueous solution Substances 0.000 abstract description 4
239000013543 active substance Substances 0.000 abstract description 2
230000002378 acidificating effect Effects 0.000 abstract 1
230000000699 topical effect Effects 0.000 abstract 1
229960000686 benzalkonium chloride Drugs 0.000 description 12
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 12
241000283973 Oryctolagus cuniculus Species 0.000 description 8
239000004480 active ingredient Substances 0.000 description 8
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 8
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 8
239000008215 water for injection Substances 0.000 description 8
239000004584 polyacrylic acid Substances 0.000 description 6
JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 description 5
239000002253 acid Substances 0.000 description 5
229940061607 dibasic sodium phosphate Drugs 0.000 description 5
238000001179 sorption measurement Methods 0.000 description 5
210000001742 aqueous humor Anatomy 0.000 description 4
230000009286 beneficial effect Effects 0.000 description 4
239000000499 gel Substances 0.000 description 4
229940045641 monobasic sodium phosphate Drugs 0.000 description 4
239000008223 sterile water Substances 0.000 description 4
229910000397 disodium phosphate Inorganic materials 0.000 description 3
235000019800 disodium phosphate Nutrition 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
239000007788 liquid Substances 0.000 description 3
238000000034 method Methods 0.000 description 3
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 2
206010018307 Glaucoma and ocular hypertension Diseases 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
239000000654 additive Substances 0.000 description 2
UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
239000002585 base Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
229960002896 clonidine Drugs 0.000 description 2
210000004087 cornea Anatomy 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000003889 eye drop Substances 0.000 description 2
229940012356 eye drops Drugs 0.000 description 2
238000001914 filtration Methods 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
239000012456 homogeneous solution Substances 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 2
229960001802 phenylephrine Drugs 0.000 description 2
229920006254 polymer film Polymers 0.000 description 2
239000011148 porous material Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
WLRMANUAADYWEA-NWASOUNVSA-N (S)-timolol maleate Chemical compound OC(=O)\C=C/C(O)=O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 WLRMANUAADYWEA-NWASOUNVSA-N 0.000 description 1
PZJFUNZDCRKXPZ-UHFFFAOYSA-N 2,5-dihydro-1h-tetrazole Chemical compound C1NNN=N1 PZJFUNZDCRKXPZ-UHFFFAOYSA-N 0.000 description 1
CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 1
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
229930003347 Atropine Natural products 0.000 description 1
229940122072 Carbonic anhydrase inhibitor Drugs 0.000 description 1
ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
230000002730 additional effect Effects 0.000 description 1
230000001800 adrenalinergic effect Effects 0.000 description 1
239000000464 adrenergic agent Substances 0.000 description 1
239000003732 agents acting on the eye Substances 0.000 description 1
239000000556 agonist Substances 0.000 description 1
150000001409 amidines Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
230000001387 anti-histamine Effects 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
239000000043 antiallergic agent Substances 0.000 description 1
229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
229960002610 apraclonidine Drugs 0.000 description 1
IEJXVRYNEISIKR-UHFFFAOYSA-N apraclonidine Chemical compound ClC1=CC(N)=CC(Cl)=C1NC1=NCCN1 IEJXVRYNEISIKR-UHFFFAOYSA-N 0.000 description 1
239000000607 artificial tear Substances 0.000 description 1
RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
229960000396 atropine Drugs 0.000 description 1
150000007514 bases Chemical class 0.000 description 1
NWIUTZDMDHAVTP-UHFFFAOYSA-N betaxolol Chemical compound C1=CC(OCC(O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-UHFFFAOYSA-N 0.000 description 1
239000000337 buffer salt Substances 0.000 description 1
229960001631 carbomer Drugs 0.000 description 1
239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
229960001803 cetirizine Drugs 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
229960003260 chlorhexidine Drugs 0.000 description 1
239000000812 cholinergic antagonist Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
SKYSRIRYMSLOIN-UHFFFAOYSA-N cyclopentolate Chemical compound C1CCCC1(O)C(C(=O)OCCN(C)C)C1=CC=CC=C1 SKYSRIRYMSLOIN-UHFFFAOYSA-N 0.000 description 1
229960001815 cyclopentolate Drugs 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
239000002389 essential drug Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
239000003337 fertilizer Substances 0.000 description 1
239000013020 final formulation Substances 0.000 description 1
230000009969 flowable effect Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000012458 free base Substances 0.000 description 1
229960005150 glycerol Drugs 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
230000004410 intraocular pressure Effects 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
HRLIOXLXPOHXTA-UHFFFAOYSA-N medetomidine Chemical compound C=1C=CC(C)=C(C)C=1C(C)C1=CN=C[N]1 HRLIOXLXPOHXTA-UHFFFAOYSA-N 0.000 description 1
229960002140 medetomidine Drugs 0.000 description 1
BQIPXWYNLPYNHW-UHFFFAOYSA-N metipranolol Chemical compound CC(C)NCC(O)COC1=CC(C)=C(OC(C)=O)C(C)=C1C BQIPXWYNLPYNHW-UHFFFAOYSA-N 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
229960001180 norfloxacin Drugs 0.000 description 1
229940125702 ophthalmic agent Drugs 0.000 description 1
229940100655 ophthalmic gel Drugs 0.000 description 1
229940023490 ophthalmic product Drugs 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
239000013074 reference sample Substances 0.000 description 1
238000000518 rheometry Methods 0.000 description 1
239000000523 sample Substances 0.000 description 1
150000003335 secondary amines Chemical group 0.000 description 1
125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
125000001302 tertiary amino group Chemical group 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229960004906 thiomersal Drugs 0.000 description 1
229960005221 timolol maleate Drugs 0.000 description 1
NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
229960000707 tobramycin Drugs 0.000 description 1
238000012546 transfer Methods 0.000 description 1
229960004791 tropicamide Drugs 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
238000009736 wetting Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Inorganic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

BG100914A 1994-03-31 1996-10-16 Офталмологичен състав, съдържащ йонночувствителенхидрофилен полимер и неорганична сол в съотношение, водещо до понижен вискозитет BG63144B1 (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9401109A SE9401109D0 (sv)	1994-03-31	1994-03-31	Opthalmic composition II
PCT/FI1995/000167 WO1995026712A1 (en)	1994-03-31	1995-03-29	Ophthalmic composition containing an ion sensitive, hydrophilic polymer and an inorganic salt in a ratio which gives low viscosity

Publications (2)

Publication Number	Publication Date
BG100914A BG100914A (en)	1997-07-31
BG63144B1 true BG63144B1 (bg)	2001-05-31

Family

ID=20393512

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG100914A BG63144B1 (bg)	1994-03-31	1996-10-16	Офталмологичен състав, съдържащ йонночувствителенхидрофилен полимер и неорганична сол в съотношение, водещо до понижен вискозитет

Country Status (25)

Country	Link
US (1)	US5795913A (de)
EP (1)	EP0755246B1 (de)
JP (1)	JPH10503471A (de)
KR (1)	KR970702025A (de)
CN (1)	CN1114399C (de)
AT (1)	ATE220538T1 (de)
AU (1)	AU694498B2 (de)
BG (1)	BG63144B1 (de)
BR (1)	BR9507439A (de)
CA (1)	CA2186591A1 (de)
CZ (1)	CZ286496A3 (de)
DE (2)	DE755246T1 (de)
DK (1)	DK0755246T3 (de)
EE (1)	EE03662B1 (de)
ES (1)	ES2179871T3 (de)
HU (1)	HU223070B1 (de)
MX (1)	MX9603919A (de)
NO (1)	NO314435B1 (de)
PL (1)	PL316585A1 (de)
PT (1)	PT755246E (de)
RO (1)	RO115410B1 (de)
RU (1)	RU2157194C2 (de)
SE (1)	SE9401109D0 (de)
SK (1)	SK281473B6 (de)
WO (1)	WO1995026712A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY116782A (en) *	1997-12-22	2004-03-31	Otsuka Pharma Co Ltd	Water-soluble eye drop
WO2000064528A1 (en)	1999-04-28	2000-11-02	Situs Corporation	Drug delivery system
AT407482B (de) *	1999-05-10	2001-03-26	Armin Dr Ettl	Kalziumantagonistische augentropfen zur prophylaktischen behandlung der cataract
US6218428B1 (en)	2000-04-28	2001-04-17	Emil Chynn	Ophthalmic composition
EP1476135A1 (de) *	2002-02-22	2004-11-17	Pharmacia Corporation	Ophthalmische formulierung mit gummi-system
US7030149B2 (en)	2002-04-19	2006-04-18	Allergan, Inc.	Combination of brimonidine timolol for topical ophthalmic use
US8877168B1 (en)	2002-07-31	2014-11-04	Senju Pharmaceuticals Co., Ltd.	Aqueous liquid preparations and light-stabilized aqueous liquid preparations
US8784789B2 (en) *	2002-07-31	2014-07-22	Senju Pharmaceutical Co., Ltd.	Aqueous liquid preparations and light-stabilized aqueous liquid preparations
US7862552B2 (en)	2005-05-09	2011-01-04	Boston Scientific Scimed, Inc.	Medical devices for treating urological and uterine conditions
DE102005035986B4 (de) *	2005-07-28	2009-10-15	Bausch & Lomb Incorporated	Steriles tropfbares mehrphasiges emulgatorfreies ophthalmisches Präparat
US20080057022A1 (en) *	2006-08-30	2008-03-06	Erning Xia	Ophthalmic Pharmaceutical Compositions and Uses Thereof
US9522153B2 (en)	2009-12-22	2016-12-20	Allergan, Inc.	Compositions and methods for lowering intraocular pressure
IL212725A (en) *	2011-05-05	2016-06-30	Resdevco Res And Dev Co	Glycerol Preparation for Non-surgical Conjunctivochalysis
EP3340982B1 (de)	2015-08-26	2021-12-15	Achillion Pharmaceuticals, Inc.	Verbindungen zur behandlung von immun- und entzündungserkrankungen
AR106018A1 (es)	2015-08-26	2017-12-06	Achillion Pharmaceuticals Inc	Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
EP3455219A4 (de)	2016-05-10	2019-12-18	C4 Therapeutics, Inc.	Amingebundene c3-glutarimiddegronimere für zielproteinabbau
KR20190003997A (ko) *	2016-06-01	2019-01-10	해롤드 리차드 헬스트롬	부교감 신경제와 항교감 신경제를 이용한 안구 건조증의 치료
CN109414441A (zh)	2016-06-27	2019-03-01	艾其林医药公司	治疗医学障碍的喹唑啉和吲哚化合物
MX2019001877A (es)	2016-08-19	2019-09-13	Orasis Pharmaceuticals Ltd	Composiciones farmaceuticas oftalmicas y usos que se relacionan a las mismas.
KR102632860B1 (ko)	2017-03-01	2024-02-02	아칠리온 파르마세우티칼스 인코포레이티드	의학적 장애의 치료를 위한 아릴, 헤테로아릴, 및 헤테로사이클릭 약학적 화합물
EP3641762B1 (de)	2017-06-20	2026-02-18	C4 Therapeutics, Inc.	N/o-gebundene degrone und degronimere zum proteinabbau
KR20210018199A (ko)	2018-03-26	2021-02-17	씨4 테라퓨틱스, 인코포레이티드	이카로스의 분해를 위한 세레블론 결합제
EP4066830A1 (de) *	2018-04-24	2022-10-05	Allergan, Inc.	Verwendung von pilocarpinhydrochlorid zur behandlung von augenkrankheiten
US20230022157A1 (en)	2018-08-20	2023-01-26	Achillion Pharmaceuticals, Inc.	Pharmaceutical compounds for the treatment of complement factor d medical disorders
EP3846803A4 (de)	2018-09-06	2022-08-10	Achillion Pharmaceuticals, Inc.	Makrocyclische verbindungen zur behandlung von medizinischen erkrankungen
WO2020081723A1 (en)	2018-10-16	2020-04-23	Georgia State University Research Foundation, Inc.	Carbon monoxide prodrugs for the treatment of medical disorders
MA55628A (fr)	2019-04-12	2022-02-16	C4 Therapeutics Inc	Agents de dégradation tricycliques d'ikaros et d'aiolos
CN115362162A (zh)	2020-02-20	2022-11-18	艾其林医药公司	用于治疗补体因子d介导的障碍的杂芳基化合物
IL295709A (en)	2020-03-05	2022-10-01	C4 Therapeutics Inc	Compounds for targeted degradation of brd9
CA3193488A1 (en)	2020-09-23	2022-03-31	Jason Allan Wiles	Pharmaceutical compounds for the treatment of complement mediated disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6056684B2 (ja) *	1977-11-07	1985-12-11	東興薬品工業株式会社	点眼剤
GB2169508B (en) *	1985-01-11	1989-02-01	Smith & Nephew Ass	Ophthalmic compositions and use
US5252318A (en) *	1990-06-15	1993-10-12	Allergan, Inc.	Reversible gelation compositions and methods of use
FR2678832B1 (fr) *	1991-07-10	1995-03-17	Europhta Sa Laboratoire	Nouvelles compositions ophtalmiques a resorption amelioree et leurs procedes de preparation.
RU2007152C1 (ru) *	1992-10-01	1994-02-15	Курский Государственный Медицинский Институт	Офтальмологическое средство и способ его получения

1994
- 1994-03-31 SE SE9401109A patent/SE9401109D0/xx unknown
1995
- 1995-03-29 EP EP95914363A patent/EP0755246B1/de not_active Expired - Lifetime
- 1995-03-29 AT AT95914363T patent/ATE220538T1/de not_active IP Right Cessation
- 1995-03-29 PL PL95316585A patent/PL316585A1/xx unknown
- 1995-03-29 US US08/535,033 patent/US5795913A/en not_active Expired - Fee Related
- 1995-03-29 JP JP7525424A patent/JPH10503471A/ja active Pending
- 1995-03-29 BR BR9507439A patent/BR9507439A/pt not_active IP Right Cessation
- 1995-03-29 PT PT95914363T patent/PT755246E/pt unknown
- 1995-03-29 AU AU21390/95A patent/AU694498B2/en not_active Ceased
- 1995-03-29 SK SK1238-96A patent/SK281473B6/sk unknown
- 1995-03-29 KR KR1019960705392A patent/KR970702025A/ko not_active Withdrawn
- 1995-03-29 RO RO96-01878A patent/RO115410B1/ro unknown
- 1995-03-29 EE EE9600157A patent/EE03662B1/xx not_active IP Right Cessation
- 1995-03-29 MX MX9603919A patent/MX9603919A/es not_active IP Right Cessation
- 1995-03-29 HU HU9602692A patent/HU223070B1/hu not_active IP Right Cessation
- 1995-03-29 DK DK95914363T patent/DK0755246T3/da active
- 1995-03-29 ES ES95914363T patent/ES2179871T3/es not_active Expired - Lifetime
- 1995-03-29 DE DE0755246T patent/DE755246T1/de active Pending
- 1995-03-29 CZ CZ962864A patent/CZ286496A3/cs unknown
- 1995-03-29 CA CA002186591A patent/CA2186591A1/en not_active Abandoned
- 1995-03-29 RU RU96119922/14A patent/RU2157194C2/ru not_active IP Right Cessation
- 1995-03-29 CN CN95192184A patent/CN1114399C/zh not_active Expired - Fee Related
- 1995-03-29 DE DE69527422T patent/DE69527422T2/de not_active Expired - Fee Related
- 1995-03-29 WO PCT/FI1995/000167 patent/WO1995026712A1/en not_active Ceased
1996
- 1996-09-27 NO NO19964071A patent/NO314435B1/no unknown
- 1996-10-16 BG BG100914A patent/BG63144B1/bg unknown

Also Published As

Publication number	Publication date
PL316585A1 (en)	1997-01-20
CZ286496A3 (en)	1997-03-12
DE755246T1 (de)	1997-09-04
PT755246E (pt)	2002-11-29
CN1114399C (zh)	2003-07-16
HU9602692D0 (en)	1996-11-28
HUT75664A (en)	1997-05-28
KR970702025A (ko)	1997-05-13
JPH10503471A (ja)	1998-03-31
DE69527422T2 (de)	2003-03-20
MX9603919A (es)	1997-04-30
RU2157194C2 (ru)	2000-10-10
EE03662B1 (et)	2002-04-15
ATE220538T1 (de)	2002-08-15
SE9401109D0 (sv)	1994-03-31
CA2186591A1 (en)	1995-10-12
NO964071D0 (no)	1996-09-27
SK123896A3 (en)	1997-06-04
AU2139095A (en)	1995-10-23
SK281473B6 (sk)	2001-04-09
BG100914A (en)	1997-07-31
AU694498B2 (en)	1998-07-23
DE69527422D1 (de)	2002-08-22
EE9600157A (et)	1997-06-16
ES2179871T3 (es)	2003-02-01
EP0755246A1 (de)	1997-01-29
DK0755246T3 (da)	2002-11-04
EP0755246B1 (de)	2002-07-17
RO115410B1 (ro)	2000-02-28
BR9507439A (pt)	1997-09-16
NO314435B1 (no)	2003-03-24
WO1995026712A1 (en)	1995-10-12
NO964071L (no)	1996-11-22
CN1144476A (zh)	1997-03-05
US5795913A (en)	1998-08-18
HU223070B1 (hu)	2004-03-01

Publication	Publication Date	Title
BG63145B1 (bg)	2001-05-31	Офталмологичен състав с понижен вискозитет
EP0755246B1 (de)	2002-07-17	Ophthalmologische zusammensetzung, die ein ionenempfindliches polymer und ein anorganisches salz in einem verhältnis enthält, das eine niedrige viskosität ergibt
US4425344A (en)	1984-01-10	Compositions for the treatment of glaucoma containing triamterene
RU2100020C1 (ru)	1997-12-27	Средство для местного лечения глазной гипертензии и глаукомы и способ его получения
US4623664A (en)	1986-11-18	Oil suspended phenylephrine
FI117921B (fi)	2007-04-30	Alennetun viskositeetin omaava oftalminen koostumus
PL172503B1 (pl)	1997-10-31	Oftalmiczny srodek do podawania miejscowego zawierajacy pólwodzian (S)-tymololu PL PL PL PL
EP4216966A1 (de)	2023-08-02	Formulierung auf der basis von polyhexamethylenbiguanid zur verwendung bei der behandlung von acanthamoeba-keratitis und/oder von pilzinfektionen
HK1013953B (en)	2002-07-05	Ophthalmic composition with decreased viscosity